Search

Your search keyword '"Yao, J.C."' showing total 193 results

Search Constraints

Start Over You searched for: Author "Yao, J.C." Remove constraint Author: "Yao, J.C."
193 results on '"Yao, J.C."'

Search Results

6. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

7. 46MO FRESCO-2: A global / multiregional phase III clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with metastatic colorectal cancer

8. LBA25 FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer

12. Analyse finale de la survie globale dans l’étude de phase 3 NETTER-1 du Lu-DOTATATE chez les patients atteints de tumeurs neuroendocrines de l’intestin moyen

19. 1102P The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses

26. Asymptotic solution for nonlinear buckling of orthotropic shells on elastic foundation

36. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

37. Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

39. Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study

40. Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

42. The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors.

48. 177 Lu-Dotatate améliore significativement la survie sans progression des patients atteints de tumeurs neuroendocrines métastatiques progressives de l’intestin moyen : résultats de l’essai de phase III NETTER-1

Catalog

Books, media, physical & digital resources